Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
Michael A NauckDarren K McGuireKaren S PieperYuliya LokhnyginaTimo E StrandbergAxel RiefflinTuncay DelibasiEric D PetersonHarvey D WhiteRussell ScottRury R HolmanPublished in: Cardiovascular diabetology (2019)
In patients with type 2 diabetes and ASCVD experiencing an MI, sitagliptin did not reduce subsequent risk of CV death or hHF, contrary to expectations derived from preclinical animal models. Trial registration clinicaltrials.gov no. NCT00790205.